Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,318 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05745623RecruitingPhase 1/Phase 2
Testing an NTRK-fusion drug for advanced tumors
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
Guangzhou, GuangdongAges 2 years+ - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT04996121RecruitingPhase 1/Phase 2
Drug for tumors with NTRK or ROS1 gene fusions
This trial studies an investigational pill (XZP-5955) for solid tumors that have specific gene changes: NTRK or ROS1 fusions. It is meant for people whose cancer is advanced or has spread, and who may not have good standard treatment options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07713550Recruiting
Genetic profiling to guide treatment for advanced solid tumors
This study tests whether analyzing the DNA of your tumor (from a tissue sample or blood draw) can help find the best treatment for your advanced cancer. Researchers will look for genetic changes that could make you eligible for targeted therapy or a clinical trial.
AnderlechtAges 18 years+ - NCT07589530RecruitingPhase 1/Phase 2
CAR NK Cell Therapy for Advanced Solid Tumors
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07042100RecruitingPhase 1
Safety study of SBO-154 for advanced solid tumors
This trial tests a new drug called SBO-154 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have few or no other treatment choices.
Scottsdale, ArizonaAges 18 years+ - NCT06566079RecruitingPhase 1/Phase 2
Study of ISM6331 for advanced mesothelioma or other solid tumors
This trial tests a new drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific pathway that may help stop tumor growth.
Denver, ColoradoAges 18 years+ - NCT06004245RecruitingPhase 1
Study of new drug for advanced solid tumors with certain genetic markers
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
Tucson, ArizonaAges 18 years+ - NCT05765851RecruitingPhase 1
A study of a new drug for advanced solid tumors with HER2
This trial tests a new combination treatment for people with advanced solid tumors that have HER2 changes. The goal is to see if it can shrink tumors or slow growth.
Sarasota, FloridaAges 18 years+ - NCT05204862RecruitingPhase 1/Phase 2
TU2218 drug with PD-1 therapy for advanced solid tumors
This Phase 1/2 study tests TU2218 by itself and with PD-1–type immunotherapy (anti–PD-(L)1) in people with advanced solid cancers. It’s designed to find a safe dose and see whether the treatment can shrink tumors when standard options have not worked.
San Antonio, TexasAges 18 years+ - NCT05911464RecruitingPhase 1
Study drug HS-10386 for advanced solid tumor cancers
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06170294RecruitingPhase 1
MAGE-A4 TCR-T therapy for advanced solid tumors
This trial tests a new type of immune therapy called MAGE-A4-directed TCR-T. It uses your own immune cells (T cells) that are modified to find and attack cancer cells that have a specific protein (MAGE-A4). It is for people with advanced solid tumors who have already tried other treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06197139RecruitingPhase 1
Study of a new targeted radiation therapy for advanced solid tumors
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
GuangzhouAges 18 years+ - NCT06211647RecruitingPhase 1
177Lu XT117 for advanced solid tumors
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
BeijingAges 18 years+ - NCT06223841RecruitingPhase 1/Phase 2
Testing IAP0971 for advanced solid tumors and lung cancer
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT06223256RecruitingPhase 1
NBL-028 for advanced solid tumors with CLDN6
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
Shijiazhuang, HebeiAges 18 years+ - NCT05877924RecruitingPhase 1
Early-phase study of an injected cancer treatment for advanced tumors
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Guanzhou, GuangdongAges 18 years+ - NCT05263479RecruitingPhase 1
Study drug for advanced solid tumors that can’t be treated
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05909241RecruitingPhase 1
First study of BA1202 for advanced solid tumors
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
BeijingAges 18–70 - NCT05649345RecruitingPhase 1
TR64 for advanced solid tumors that standard treatment failed
This early-phase trial studies TR64 in people with advanced solid cancers when standard treatments have stopped working or aren’t an option. It aims to see whether the drug can reduce tumors and is safe enough to keep studying.
Bengbu, AnhuiAges 18–75 - NCT07847281RecruitingPhase 1
New injectable drug for advanced solid tumors
This trial tests a new experimental drug (AK157D1) given by injection for people with advanced solid tumors that have not responded to standard care. The goal is to see if the drug can shrink tumors or slow their growth.
Harbin, HeilongjiangAges 18–75 - NCT07811037RecruitingPhase 1/Phase 2
Safety and effect of SGT003 for advanced solid tumors
This trial tests a new experimental medicine called SGT003 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the medicine is safe, how the body handles it, and whether it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT05979155RecruitingPhase 1
Study of NWY001 for advanced solid tumors
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,318 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.